Abstract
Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.
Publication types
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Humans
-
Melanoma / drug therapy*
-
Proto-Oncogene Proteins B-raf / genetics*
-
ras Proteins / genetics*
Substances
-
Antineoplastic Agents
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
ras Proteins